2020 quarterly results of 4 spine device companies: A breakdown of Stryker, Zimmer Biomet & more

The COVID-19 pandemic has had a significant impact on first- and second-quarter revenues of medical device companies, with the spine and orthopedic industry taking a particularly seismic blow. 

Advertisement

Here is a breakdown of key quarterly results published by Zimmer Biomet, Stryker, Globus Medical and Medtronic this year, along with the year-over-year percentage change:

First quarter

Zimmer Biomet

Net sales: $1.78 billion (-9.7 percent)
Global hips sales: $433 million (-10.5 percent)
Sports medicine, extremities and trauma sales: $333 million (-6.5 percent)
Knees sales: $629.8 million (-9.3 percent)
Dental, spine and craniomaxillofacial and thoracic sales: $252 million (-12.4 percent)

Stryker

Net sales: $3.6 billion (+2 percent)
Knees sales: $432 million (+1.7 percent)
Hips sales: $316 million (+5.9 percent)
Trauma and extremities sales: $392 million (+0.8 percent)
Neurotechnology and spine sales: $700 million (+0.7 percent)

Globus Medical

Total sales: $190.6 million (+4.2 percent)
U.S. sales (including robotics): $158.4 (+7.4 percent)
International sales: $32.1 million (-9.3 percent)
Net income: $25.9 million (-21.9 percent)

Second quarter

Zimmer Biomet

Net sales: $1.23 billion (-38.3 percent)
Global hips sales: $329.7 million (-31.1 percent)
Sports medicine, extremities and trauma sales: $252.6 million (-29.2 percent)
Knees sales: $374.2 million (-46.8 percent)
Dental, spine and craniomaxillofacial and thoracic sales: $182.5 million (-37.6 percent)

Stryker

Net sales: $2.8 billion (-24.3 percent)
Knees sales: $241 million (-45.2 percent)
Hips sales: $216 million (-37.1 percent)
Trauma and extremities sales: $330 million (-16.4 percent)
Neurotechnology and spine sales: $546 million (-29.6 percent)

Globus Medical

Total sales: $148.9 million (-23.4 percent)
U.S. sales (including robotics): $125.2 million (-21.8 percent)
International sales: $23.8 million (-31.2 percent)
Net loss: $20.8 million (-154.6 percent)

Medtronic fourth quarter (reported May 20, 2020)

Total revenue: $6 billion (-26 percent)
Spine revenue: $480 million (-31 percent)
Brain therapies revenue: $615 million (-26 percent)
Specialty therapies revenue: $197 million (-44 percent)
Pain therapies revenue: $198 million (-42 percent)

More articles on devices:
Dr. Zarina Ali creates program to reduce opioid use post-spine surgery
Dr. Chris Dodson performs knee surgery on 76ers star Ben Simmons — 4 insights
Neurosurgeon beaten in Republican runoff for Georgia’s US House seat

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.